A 1-year pilot study of vagus nerve stimulation in treatment-resistant rapid-cycling bipolar disorder

Lauren B. Marangell, Trisha Suppes, Holly A. Zboyan, Sandhya J. Prashad, Grace Fischer, Diane Snow, Suresh Sureddi, John C. Allen

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Objective: Vagus nerve stimulation (VNS) appears to be an effective treatment option for patients with treatment-resistant unipolar and bipolar depression. The aim of the present study was to investigate the efficacy of VNS in a group of patients with treatment-resistant rapid-cycling bipolar disorder (RCBD) who were excluded from previous trials. Method: Nine outpatients with a DSM-IV-TR diagnosis of treatment-resistant RCBD were treated for 40 weeks with open-label VNS. The first patient was enrolled in June 2001, and the last patient completed the study in July 2005. Patients recorded their depression and mania mood symptoms on a daily basis throughout the study using the National Institute of Mental Health prospective life charting methodology and daily mood ratings. Patients were assessed every 2 weeks during the 2-month baseline period before device activation, every 2 weeks for the remaining 40 weeks of the study, and at the end of the study with the 24-item Hamilton Rating Scale for Depression (HAM-D-24), the 10-item Montgomery-Asberg Depression Rating Scale (MADRS), the Young Mania Rating Scale (YMRS), the Clinical Global Impressions (CGI) scale, the Global Assessment of Functioning (GAF) scale, and the 30-item Inventory of Depressive Symptomatology Self-Report (IDS-SR-30). Any adverse events or device complications were also recorded at each visit. The prospective life charts were analyzed by calculating the area under the curve. Statistical analysis was performed with a mixed-model repeated-measures regression analysis for repeated measures of the various rating scales. Significant p values were ≤ .05. Results: Over the 12-month study period, VNS was associated with a 38.1% mean improvement in overall illness as compared to baseline (p = .012), as well as significant reductions in symptoms as measured by the HAM-D-24 (p = .043), MADRS (p = .003), CGI (p = .013), and GAF (p < .001) rating scales. Common adverse events were voice alteration during stimulation and hoarseness. Conclusion: These data suggest that VNS may be an efficacious and well-tolerated treatment option for patients with treatment-resistant RCBD. Currently, no comparison is available in the literature. Larger randomized trials are needed to verify these findings.

Original languageEnglish (US)
Pages (from-to)183-189
Number of pages7
JournalJournal of Clinical Psychiatry
Volume69
Issue number2
StatePublished - Feb 2008

Fingerprint

Vagus Nerve Stimulation
Bipolar Disorder
Depression
Equipment and Supplies
Therapeutics
Treatment-Resistant Depressive Disorder
National Institute of Mental Health (U.S.)
Hoarseness
Depressive Disorder
Diagnostic and Statistical Manual of Mental Disorders
Self Report
Area Under Curve
Outpatients
Regression Analysis

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Marangell, L. B., Suppes, T., Zboyan, H. A., Prashad, S. J., Fischer, G., Snow, D., ... Allen, J. C. (2008). A 1-year pilot study of vagus nerve stimulation in treatment-resistant rapid-cycling bipolar disorder. Journal of Clinical Psychiatry, 69(2), 183-189.

A 1-year pilot study of vagus nerve stimulation in treatment-resistant rapid-cycling bipolar disorder. / Marangell, Lauren B.; Suppes, Trisha; Zboyan, Holly A.; Prashad, Sandhya J.; Fischer, Grace; Snow, Diane; Sureddi, Suresh; Allen, John C.

In: Journal of Clinical Psychiatry, Vol. 69, No. 2, 02.2008, p. 183-189.

Research output: Contribution to journalArticle

Marangell, LB, Suppes, T, Zboyan, HA, Prashad, SJ, Fischer, G, Snow, D, Sureddi, S & Allen, JC 2008, 'A 1-year pilot study of vagus nerve stimulation in treatment-resistant rapid-cycling bipolar disorder', Journal of Clinical Psychiatry, vol. 69, no. 2, pp. 183-189.
Marangell LB, Suppes T, Zboyan HA, Prashad SJ, Fischer G, Snow D et al. A 1-year pilot study of vagus nerve stimulation in treatment-resistant rapid-cycling bipolar disorder. Journal of Clinical Psychiatry. 2008 Feb;69(2):183-189.
Marangell, Lauren B. ; Suppes, Trisha ; Zboyan, Holly A. ; Prashad, Sandhya J. ; Fischer, Grace ; Snow, Diane ; Sureddi, Suresh ; Allen, John C. / A 1-year pilot study of vagus nerve stimulation in treatment-resistant rapid-cycling bipolar disorder. In: Journal of Clinical Psychiatry. 2008 ; Vol. 69, No. 2. pp. 183-189.
@article{793870c8150f414c9441ba097d313b3b,
title = "A 1-year pilot study of vagus nerve stimulation in treatment-resistant rapid-cycling bipolar disorder",
abstract = "Objective: Vagus nerve stimulation (VNS) appears to be an effective treatment option for patients with treatment-resistant unipolar and bipolar depression. The aim of the present study was to investigate the efficacy of VNS in a group of patients with treatment-resistant rapid-cycling bipolar disorder (RCBD) who were excluded from previous trials. Method: Nine outpatients with a DSM-IV-TR diagnosis of treatment-resistant RCBD were treated for 40 weeks with open-label VNS. The first patient was enrolled in June 2001, and the last patient completed the study in July 2005. Patients recorded their depression and mania mood symptoms on a daily basis throughout the study using the National Institute of Mental Health prospective life charting methodology and daily mood ratings. Patients were assessed every 2 weeks during the 2-month baseline period before device activation, every 2 weeks for the remaining 40 weeks of the study, and at the end of the study with the 24-item Hamilton Rating Scale for Depression (HAM-D-24), the 10-item Montgomery-Asberg Depression Rating Scale (MADRS), the Young Mania Rating Scale (YMRS), the Clinical Global Impressions (CGI) scale, the Global Assessment of Functioning (GAF) scale, and the 30-item Inventory of Depressive Symptomatology Self-Report (IDS-SR-30). Any adverse events or device complications were also recorded at each visit. The prospective life charts were analyzed by calculating the area under the curve. Statistical analysis was performed with a mixed-model repeated-measures regression analysis for repeated measures of the various rating scales. Significant p values were ≤ .05. Results: Over the 12-month study period, VNS was associated with a 38.1{\%} mean improvement in overall illness as compared to baseline (p = .012), as well as significant reductions in symptoms as measured by the HAM-D-24 (p = .043), MADRS (p = .003), CGI (p = .013), and GAF (p < .001) rating scales. Common adverse events were voice alteration during stimulation and hoarseness. Conclusion: These data suggest that VNS may be an efficacious and well-tolerated treatment option for patients with treatment-resistant RCBD. Currently, no comparison is available in the literature. Larger randomized trials are needed to verify these findings.",
author = "Marangell, {Lauren B.} and Trisha Suppes and Zboyan, {Holly A.} and Prashad, {Sandhya J.} and Grace Fischer and Diane Snow and Suresh Sureddi and Allen, {John C.}",
year = "2008",
month = "2",
language = "English (US)",
volume = "69",
pages = "183--189",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "2",

}

TY - JOUR

T1 - A 1-year pilot study of vagus nerve stimulation in treatment-resistant rapid-cycling bipolar disorder

AU - Marangell, Lauren B.

AU - Suppes, Trisha

AU - Zboyan, Holly A.

AU - Prashad, Sandhya J.

AU - Fischer, Grace

AU - Snow, Diane

AU - Sureddi, Suresh

AU - Allen, John C.

PY - 2008/2

Y1 - 2008/2

N2 - Objective: Vagus nerve stimulation (VNS) appears to be an effective treatment option for patients with treatment-resistant unipolar and bipolar depression. The aim of the present study was to investigate the efficacy of VNS in a group of patients with treatment-resistant rapid-cycling bipolar disorder (RCBD) who were excluded from previous trials. Method: Nine outpatients with a DSM-IV-TR diagnosis of treatment-resistant RCBD were treated for 40 weeks with open-label VNS. The first patient was enrolled in June 2001, and the last patient completed the study in July 2005. Patients recorded their depression and mania mood symptoms on a daily basis throughout the study using the National Institute of Mental Health prospective life charting methodology and daily mood ratings. Patients were assessed every 2 weeks during the 2-month baseline period before device activation, every 2 weeks for the remaining 40 weeks of the study, and at the end of the study with the 24-item Hamilton Rating Scale for Depression (HAM-D-24), the 10-item Montgomery-Asberg Depression Rating Scale (MADRS), the Young Mania Rating Scale (YMRS), the Clinical Global Impressions (CGI) scale, the Global Assessment of Functioning (GAF) scale, and the 30-item Inventory of Depressive Symptomatology Self-Report (IDS-SR-30). Any adverse events or device complications were also recorded at each visit. The prospective life charts were analyzed by calculating the area under the curve. Statistical analysis was performed with a mixed-model repeated-measures regression analysis for repeated measures of the various rating scales. Significant p values were ≤ .05. Results: Over the 12-month study period, VNS was associated with a 38.1% mean improvement in overall illness as compared to baseline (p = .012), as well as significant reductions in symptoms as measured by the HAM-D-24 (p = .043), MADRS (p = .003), CGI (p = .013), and GAF (p < .001) rating scales. Common adverse events were voice alteration during stimulation and hoarseness. Conclusion: These data suggest that VNS may be an efficacious and well-tolerated treatment option for patients with treatment-resistant RCBD. Currently, no comparison is available in the literature. Larger randomized trials are needed to verify these findings.

AB - Objective: Vagus nerve stimulation (VNS) appears to be an effective treatment option for patients with treatment-resistant unipolar and bipolar depression. The aim of the present study was to investigate the efficacy of VNS in a group of patients with treatment-resistant rapid-cycling bipolar disorder (RCBD) who were excluded from previous trials. Method: Nine outpatients with a DSM-IV-TR diagnosis of treatment-resistant RCBD were treated for 40 weeks with open-label VNS. The first patient was enrolled in June 2001, and the last patient completed the study in July 2005. Patients recorded their depression and mania mood symptoms on a daily basis throughout the study using the National Institute of Mental Health prospective life charting methodology and daily mood ratings. Patients were assessed every 2 weeks during the 2-month baseline period before device activation, every 2 weeks for the remaining 40 weeks of the study, and at the end of the study with the 24-item Hamilton Rating Scale for Depression (HAM-D-24), the 10-item Montgomery-Asberg Depression Rating Scale (MADRS), the Young Mania Rating Scale (YMRS), the Clinical Global Impressions (CGI) scale, the Global Assessment of Functioning (GAF) scale, and the 30-item Inventory of Depressive Symptomatology Self-Report (IDS-SR-30). Any adverse events or device complications were also recorded at each visit. The prospective life charts were analyzed by calculating the area under the curve. Statistical analysis was performed with a mixed-model repeated-measures regression analysis for repeated measures of the various rating scales. Significant p values were ≤ .05. Results: Over the 12-month study period, VNS was associated with a 38.1% mean improvement in overall illness as compared to baseline (p = .012), as well as significant reductions in symptoms as measured by the HAM-D-24 (p = .043), MADRS (p = .003), CGI (p = .013), and GAF (p < .001) rating scales. Common adverse events were voice alteration during stimulation and hoarseness. Conclusion: These data suggest that VNS may be an efficacious and well-tolerated treatment option for patients with treatment-resistant RCBD. Currently, no comparison is available in the literature. Larger randomized trials are needed to verify these findings.

UR - http://www.scopus.com/inward/record.url?scp=41549116887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41549116887&partnerID=8YFLogxK

M3 - Article

VL - 69

SP - 183

EP - 189

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 2

ER -